NZ589690A - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators - Google Patents

Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

Info

Publication number
NZ589690A
NZ589690A NZ589690A NZ58969009A NZ589690A NZ 589690 A NZ589690 A NZ 589690A NZ 589690 A NZ589690 A NZ 589690A NZ 58969009 A NZ58969009 A NZ 58969009A NZ 589690 A NZ589690 A NZ 589690A
Authority
NZ
New Zealand
Prior art keywords
pyridin
hydroxy
dihydro
thieno
phenyl
Prior art date
Application number
NZ589690A
Other languages
English (en)
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Christine Charon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ589690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NZ589690A publication Critical patent/NZ589690A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ589690A 2008-05-05 2009-04-08 Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators NZ589690A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (1)

Publication Number Publication Date
NZ589690A true NZ589690A (en) 2012-07-27

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589690A NZ589690A (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

Country Status (26)

Country Link
US (1) US8604202B2 (enExample)
EP (1) EP2280952B1 (enExample)
JP (1) JP5536757B2 (enExample)
KR (2) KR101648593B1 (enExample)
CN (1) CN102015676B (enExample)
AR (1) AR071530A1 (enExample)
AU (1) AU2009243811B2 (enExample)
BR (1) BRPI0910832B8 (enExample)
CA (1) CA2723429C (enExample)
CO (1) CO6331304A2 (enExample)
CY (1) CY1113112T1 (enExample)
DK (1) DK2280952T3 (enExample)
EA (1) EA020773B1 (enExample)
EC (1) ECSP10010654A (enExample)
ES (1) ES2388485T3 (enExample)
HR (1) HRP20120549T1 (enExample)
IL (1) IL208988A (enExample)
MX (1) MX2010011916A (enExample)
MY (1) MY160357A (enExample)
NZ (1) NZ589690A (enExample)
PL (1) PL2280952T3 (enExample)
PT (1) PT2280952E (enExample)
SI (1) SI2280952T1 (enExample)
UA (1) UA103617C2 (enExample)
WO (1) WO2009135580A1 (enExample)
ZA (1) ZA201008722B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
RU2013114184A (ru) * 2010-09-01 2014-10-10 Байер Интеллектуэль Проперти Гмбх Гербицидно-активные кетосультамы и дикетопиридины
CN103517896B (zh) * 2011-03-07 2016-09-21 葛兰素史密斯克莱有限责任公司 喹啉酮衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
WO2016205534A1 (en) * 2015-06-16 2016-12-22 Lazo John S Inhibitors of ptp4a3 for the treatment of cancer
SG10202105964RA (en) * 2015-06-25 2021-07-29 Univ Health Network Hpk1 inhibitors and methods of using same
CN108463218A (zh) 2015-09-30 2018-08-28 药物分子研究所 减弱寄生虫毒性的方法
US11584755B2 (en) 2017-09-26 2023-02-21 Ideaya Biosciences, Inc. Dihydrothieno[3,2-b]pyridine compounds
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
WO2023092094A2 (en) 2021-11-19 2023-05-25 The Broad Institute, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) * 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
US20090149495A1 (en) * 2005-12-20 2009-06-11 Katalin Nogradi Compounds
AU2009235784B2 (en) * 2008-04-11 2013-09-19 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

Also Published As

Publication number Publication date
US20110060001A1 (en) 2011-03-10
CN102015676B (zh) 2014-05-28
JP5536757B2 (ja) 2014-07-02
KR20110010757A (ko) 2011-02-07
EP2280952B1 (en) 2012-06-27
CO6331304A2 (es) 2011-10-20
DK2280952T3 (da) 2012-07-23
EA201001733A1 (ru) 2011-06-30
CA2723429A1 (en) 2009-11-12
PL2280952T3 (pl) 2012-10-31
BRPI0910832B1 (pt) 2020-09-15
KR101648593B1 (ko) 2016-08-16
EA020773B1 (ru) 2015-01-30
US8604202B2 (en) 2013-12-10
AR071530A1 (es) 2010-06-23
IL208988A (en) 2016-02-29
AU2009243811A1 (en) 2009-11-12
ZA201008722B (en) 2012-01-25
ES2388485T3 (es) 2012-10-15
HRP20120549T1 (hr) 2012-07-31
BRPI0910832A8 (pt) 2016-07-12
EP2280952A1 (en) 2011-02-09
UA103617C2 (ru) 2013-11-11
PT2280952E (pt) 2012-09-28
JP2011519876A (ja) 2011-07-14
HK1156313A1 (en) 2012-06-08
KR20160038065A (ko) 2016-04-06
IL208988A0 (en) 2011-01-31
BRPI0910832B8 (pt) 2021-05-25
CA2723429C (en) 2016-10-11
MX2010011916A (es) 2010-11-26
CN102015676A (zh) 2011-04-13
BRPI0910832A2 (pt) 2015-08-11
ECSP10010654A (es) 2011-01-31
SI2280952T1 (sl) 2012-09-28
MY160357A (en) 2017-02-28
CY1113112T1 (el) 2016-04-13
WO2009135580A1 (en) 2009-11-12
AU2009243811B2 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
CA2723429C (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
CA2721025C (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
EP2285786B1 (en) Quinoxalinedione derivatives
HK1155955B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
HK1156313B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 APR 2016 BY CPA GLOBAL

Effective date: 20130308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2017 BY CPA GLOBAL

Effective date: 20160304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2018 BY CPA GLOBAL

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2019 BY CPA GLOBAL

Effective date: 20180301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2021 BY CPA GLOBAL

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2022 BY CPA GLOBAL

Effective date: 20210305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2023 BY CPA GLOBAL

Effective date: 20220304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2024 BY CPA GLOBAL

Effective date: 20230303

LAPS Patent lapsed